We have a robust pipeline of clinical assets including cancer cell-directed therapies, for which we are investigating the key drivers of cancer such as P53 and KRAS.
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Boehringer Ingelheim produces lay summaries of clinical trials, making complex information and data from clinical studies understandable for patients and carers.